Monash IVF Could Become a Takeover Target for Private Equity -- Market Talk

Dow Jones

Jun 13, 2025

0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. "With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at >12x) we see increased risk of Private equity/strategic interest," Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

June 12, 2025 20:59 ET (00:59 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2543529041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543529041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543529041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 08:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543529041","market":"hk","top_or_hot":-1,"title":"Monash IVF Could Become a Takeover Target for Private Equity -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. \"With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at &gt;12x) we see increased risk of Private equity/strategic interest,\" Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2025 20:59 ET (00:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monash IVF Could Become a Takeover Target for Private Equity -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonash IVF Could Become a Takeover Target for Private Equity -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-13 08:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. \"With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at &gt;12x) we see increased risk of Private equity/strategic interest,\" Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2025 20:59 ET (00:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2543529041","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543529041","pubTimestamp":1749776340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. \"With Monash IVF now trading at 6.7x adjusted Ebitda  we see increased risk of Private equity/strategic interest,\" Ord Minnett says. Monash IVF is up 1.5% at A$0.67. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4082":"医疗保健设备","BK4585":"ETF&股票定投概念","BK7508":"医药生物股","EQR":"资产住宅公司","BK4215":"住宅房地产投资信托","MVF.AU":"MONASH IVF GROUP LTD","IVF":"INVO Fertility, Inc","BK7113":"保健护理机构"},"translate_title":"莫纳什IVF可能成为私募股权的收购目标——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVF":1,"MVF.AU":0.9,"EQR":1},"content_text":"0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. \"With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at >12x) we see increased risk of Private equity/strategic interest,\" Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2025 20:59 ET (00:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}